Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Aminex Therapeutics, Inc.
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05500508CT.gov Oral AMXT 1501 Dicaprate in Combination With IV DFMO | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pleural Mesothelioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Eflornithine (this asset) | Aminex Therapeutics, Inc. | P1/2 | CCC · 48 |
| Nivolumab | TCR2 Therapeutics | P1/2 | CCC |
| Ipilimumab | TCR2 Therapeutics | P1/2 | CCC |
| Regorafenib | Institut Bergonié | P1/2 | CCC |
| Rso-021 | RS Oncology LLC | P1/2 | CCC |
| Fludarabine | TCR2 Therapeutics | P1/2 | CCC |
| tc-510 | TCR2 Therapeutics | P1/2 | CCC |
| Amxt1501 | Aminex Therapeutics, Inc. | P1/2 | CCC |
| Cyclophosphamide | TCR2 Therapeutics | P1/2 | CCC |
+4 more in the Pleural Mesothelioma cohort
Other indications for Eflornithine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Classic Familial Adenomatous Polyposis | — | P3 | BB · 66 |
| Precancerous Condition | — | P3 | BB · 64 |
| Colon Adenoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Eflornithine in Pleural Mesothelioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/eflornithine-pleural-mesothelioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →